Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PASylated asparaginase
- Development stage
- Preclinical
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
PASylated asparaginase is a long-acting recombinant enzyme therapy being developed for the treatment of acute lymphoblastic leukemia (ALL). It consists of the enzyme asparaginase (specifically crisantaspase) modified using XL-protein's proprietary PASylation technology. PASylation involves the genetic fusion or chemical conjugation of the therapeutic protein with a conformationally disordered polypeptide composed of proline, alanine, and serine (PAS) amino acids. This modification increases the hydrodynamic volume of the protein, thereby extending its plasma half-life and duration of therapeutic effect by reducing renal clearance. The drug works by depleting circulating asparagine, an amino acid that leukemic cells are unable to synthesize themselves, leading to cell death. The program is currently in preclinical development through a collaboration between XL-protein and Jazz Pharmaceuticals.
- Other names
- PASylated recombinant crisantaspasePASylated crisantaspase
Beyond the preview
Go deeper on PASylated asparaginase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PASylated asparaginase.